Novartis

$87.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-0.63%) Today
-$1.43 (-1.62%) As of 6:59 PM EDT after-hours

Why Robinhood?

You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!

About NVS

Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Employees
125,161
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1996
Market Cap
202.34B
Price-Earnings Ratio
17.91
Dividend Yield
2.15
Average Volume
1.63M
High Today
$89.92
Low Today
$88.21
Open Price
$89.50
Volume
2.12M
52 Week High
$96.31
52 Week Low
$74.97

Collections

NVS News

Wall Street JournalAug 22

FDA Focuses on Novartis Delay in Reporting Drug-Test Data Manipulation

25
CNBCAug 20

Ousted Novartis scientist 'categorically denies' wrongdoing in data manipulation scandal

18
Wall Street JournalAug 18

Novartis CEO Battles Fallout From Data Manipulation

136

NVS Earnings

$1.20
$1.25
$1.29
$1.34
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 22, Pre-Market

More NVS News

BloombergAug 18

Novartis Insider Sold Shares in Weeks Before Zolgensma Scandal

61
ReutersAug 14

Novartis replaces top scientists at Avexis after drug data manipulated

28
Wall Street JournalAug 14

Novartis Replaces Two Researchers Amid Data Scandal

6
Barron'sAug 14

Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine

104
Financial PostAug 12

Senator Grassley seeks info on Novartis's Zolgensma data issues

11
Washington PostAug 10

Drugmakers Put Bad Spin on a Bizarre Week

221
Financial PostAug 9

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

357
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.